Maintenance bacillus calmette-guérin treatment of non-muscle-invasive bladder cancer: A critical evaluation of the evidence

European Urology

Volumn 64, Issue 4, 2013, Pages 579-585

  Ehdaie, Behfar ^a   Sylvester, Richard ^b   Herr, Harry W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EORTC DATA CENTER   (Belgium)

Author keywords

BCG; Bladder cancer; Outcomes; Urothelial carcinoma

Indexed keywords

BCG VACCINE; MITOMYCIN;

BLADDER CANCER; CONTROL GROUP; DATA BASE; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MEDLINE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SURVIVAL; TREATMENT DURATION; TUMOR INVASION; UNSPECIFIED SIDE EFFECT;

BCG; BLADDER CANCER; OUTCOMES; UROTHELIAL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; BCG VACCINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84883745873     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.027     Document Type: Review

References (26)

1. A. Morales, D. Eidinger, and A.W. Bruce Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors J Urol 116 1976 180 183
2. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
3. M.C. Hall, S.S. Chang, and G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314 2330
4. J.E. Montie, P.E. Clark, and M.A. Eisenberger Bladder cancer J Natl Compr Canc Netw 7 2009 8 39
5. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study J Urol 163 2000 1124 1129
6. S. Hinotsu, H. Akaza, and S. Naito Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer BJU Int 108 2011 187 195
7. H. Koga, S. Ozono, and T. Tsushima Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group Int J Urol 17 2010 759 766
8. R.A. Badalament, H.W. Herr, and G.Y. Wong A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette- Guérin therapy of superficial bladder cancer J Clin Oncol 5 1987 441 449
9. H. Akaza, S. Hinotsu, and Y. Aso Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group Cancer 75 1995 552 559
10. M.A. Hudson, T.L. Ratliff, and D.P. Gillen Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: a prospective, randomized trial J Urol 138 1987 295 298
11. J. Palou, P. Laguna, and F. Millan-Rodriguez Control group and maintenance treatment with bacillus Calmette-Guérin for carcinoma in situ and/or high grade bladder tumors J Urol 165 2001 1488 1491
12. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86-91; discussion 91-2.
13. P.U. Malmstrom, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin c versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
14. A. Böhle Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials Int Braz J Urol 28 2002 585 586
15. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-6; discussion 686-7.
16. A. Böhle, D. Jocham, and P.R. Bock Intravesical bacillus Calmette-Guérin versus mitomycin c for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 2003 90 95
17. R.F. Han, and J.G. Pan Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials Urology 67 2006 1216 1223
18. R.J. Sylvester, A.P. van der van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
19. H.W. Herr, D.M. Schwalb, and Z.F. Zhang Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial J Clin Oncol 13 1995 1404 1408
20. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck The side effects of bacillus Calmette-Guérin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial Eur Urol 44 2003 423 428
21. J. Oddens, M. Brausi, and R. Sylvester Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472
22. A. Ojea, J.L. Nogueira, and E. Solsona A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guérin (27 mg) versus very low-dose bacillus Calmette-Guérin (13.5 mg) versus mitomycin c Eur Urol 52 2007 1398 1406
23. H.W. Herr, G. Dalbagni, and S.M. Donat Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer Eur Urol 60 2011 32 36
24. P. Gontero, A. Böhle, and P.U. Malmstrom The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer Eur Urol 57 2010 410 429
25. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
26. M. Brausi, L. Collette, and K. Kurth Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523 531